Indira IVF, BD SurePath Joins Hand to Advance Cervical Cancer Screening in India

~The revolutionary liquid based PAP test to significantly increase the detection rate~

Bengaluru, 04 March, 2024: In a significant move to enhance cervical cancer screening accuracy and accessibility in India, Indira IVF collaborates with BD SurePath. This partnership is aimed at helping improve patient care in the country through its revolutionary Liquid-Based cytology PAP test, which significantly increases the detection rate of cervical cancer, enabling its timely treatment and prevention.

Cervical cancer ranks as the second most prevalent cancer among Indian women that claims the lives of nearly 77,348 females each year. With 123,907 new reported cases annually, untimely detection is a primary factor contributing to its critical status as a public health concern. The inaccessibility of advanced screening techniques has resulted in a large number of women being diagnosed at later stages, leading to adverse outcomes. Through this strategic collaboration, this advanced test will now be more widely available across all Indira PathLabs centres.

This DTS Pap test ensures that 100% of the collected sample is sent to the laboratory using the standardised Collect, Drop, Send method. This eliminates the risk of losing diagnostic cells during transfer, a common drawback in traditional methods where up to 37% of samples can be lost with their “rinse and swish” techniques. Apart from this, its innovative technology also enhances the laboratory’s ability to create homogenous, thin-layer slides for more accurate results.

Dr. Kshitiz Murdia, Co-founder and CEO of Indira IVF, said, “In India, the mortality rate from cervical cancer is eight times higher compared to developed nations, yet awareness and accessibility for its advanced detection remain at a very low level. With medical technologies demonstrating remarkable results in patient care and early detection of life-threatening diseases, we believe that such technology will bring unprecedented efficiency to cervical cancer screening in our country. Indira IVF has consistently aimed at elevating the standard of women’s healthcare by providing efficient and reliable treatment, thereby empowering them with proactive and advanced medical care. The expertise and acumen of our clinicians, combined with the finesse of such technologies, undoubtedly allow us to extend our services beyond mere treatment to comprehensive patient well-being.”

Human Papilloma Virus (HPV) infection is a leading cause of cervical cancer, and timely screening is crucial for early detection and prevention. The Federation of Obstetric and Gynaecological Societies of India (FOGSI) recommends cervical cancer screening to start at 25 years in high-resource settings and 30 years in low-resource settings.